We have taken advantage of a natural experiment to measure the impact of the phased abolition of prescription co-payments in Wales. We investigated 3 study periods covering the phased abolition: from £6 to £4, £4 to £3, and £3 to £0. A difference-in-difference modelling was adopted and applied to monthly UK general practice level dispensing data on 14 selected medicines which had the highest percentage of items dispensed subject to a co-payment prior to abolition.
| INTRODUCTION
Globally, there has been a substantial growth in government health expenditure due to increased health care costs (Dieleman, Templin, Sadat, et al., 2016) . To offset some of these costs, co-payment systems have been an aspect of healthcare in many countries (Austvoll-Dahlgren et al., 2008) , including the UK, where co-payment for prescription medicines has been in the form of a flat fee per item dispensed to NHS patients.
A unified approach to prescription co-payment had been applied across all parts of the UK (England, Wales, Scotland, and Northern Ireland) up to 2000 when the Welsh Assembly Government froze the co-payment at its then current level of £6 per item. A phased reduction began in October 2004, with abolition in April 2007. During this period, the co-payment increased steadily in nominal terms in other parts of the UK, but in real terms was virtually constant (Figure 1) .
Assessment of the effects of the Welsh policy provided two unique opportunities. First, whereas all previous studies in the UK and most other countries examined the effects of increasing costs to patients, the new Welsh policy allowed examination of the effects of reducing and ultimately abolishing them. Second, the Welsh policy provided a natural experiment which, for the first time, allowed a comparison of dispensing rates between a geographical area which experienced a significant change in the co-payment with another where it remained broadly constant after taking account of inflation.
The international literature consistently shows that an increase in co-payment leads to a decrease in the probability of prescription use, the number of drugs utilised, and prescription drugs expenditures (Goldman, Joyce, & Zeng, 2007; Leibowitz, Manning, & Newhouse, 1985; Lexchin & Grootendorst, 2004; McManus et al., 1996; Tamblyn, Laprise, Hanley, et al., 2001) . Price elasticity of utilisation is a common, unitless measure which describes the responsive of demand for prescription medicines (Gemmill, Costa-Fon, & McGuire, 2008) . The relationship between co-payment and drug utilization can be seen in reviews by Barnieh, Clement, Harris, et al. (2013) , Gemmill et al. (2008) and Gibson, Ozminkowski, and Goetzel (2005) . Several previous studies have estimated the price elasticity of prescription medicines utilisation in the UK mainly using national-level, aggregated dispensing data and producing price elasticity estimates ranging from −0.64 to −0.09 (Hughes & McGuire, 1995; Lavers, 1989; O'Brien, 1989; Ryan & Birch, 1991) . Whereas estimates from other countries are mainly in line with this (Fiorio & Siciliani, 2010; Grootendorst & Levine, 2001; Klick & Stratmann, 2005; Motheral & Henderson, 1999; Puig-Junoy, 1988; Smith, 1993; Street, Jones, & Furuta, 1999; Van et al., 1999) , there remains significant heterogeneity, because the type of data used, method of analysis applied, subpopulations considered, and other factors vary across studies (Gemmill et al., 2008) .
Although in the UK prescriptions for certain medical conditions are exempt from co-payment, most exemptions relate to individuals regardless of their condition. These include, inter alia, older people, children, pregnant women, NHS in-patients, and those receiving various forms of income support. As a result, approximately half the UK population has always been exempt from co-payment (Walley, 1998) . In 2003/4, 89% of items dispensed in the community in Wales were not subject to co-payment (Health Solutions Wales, 2004) . Any effect of policy changes on total dispensing would therefore be mitigated by the fact that dispensing of most medicines would be only minimally affected if at all.
We aimed to estimate the relationship between changes in prescription co-payments and changes in dispensing rates in Wales during the period October 2003 to March 2008 focussing on those medicines which had the highest number of items dispensed with a co-payment prior to abolition as these are the ones most likely to be affected by any changes to co-payments.
| METHODS
The utilisation of prescription medicines is clearly not solely a function of price, and previous studies have included a range of other variables including "price of substitutes," "sickness benefit," "working population," etc. We avoided any assumptions of confounding effects by using North East England as a comparator area which closely resembles Wales in terms of key health and socio-economic characteristics (Table 1) . Further, we surveyed all Health Boards in Wales and all Primary Care Trusts in NE England (essentially the bodies which receive funding to secure or provide health care to those living in defined geographical areas) to identify any differences in local prescribing policies and initiatives which could have differentially impacted on dispensing rates. Although there was evidence of some local factors that might have influenced dispensing rates, responses from both areas were broadly in accord . We could therefore conclude that the influence on dispensing rates of all factors other than price was likely to be similar for the two areas over the period of study. We selected the 14 medicines (strictly, 15 but with two strengths of amoxicillin; Table 2 ) from a list of the 100 dispensed medicinal preparations that most frequently incurred a co-payment in Wales in April 2005. No medicine had more that 25% of items dispensed subject to co-payment in Wales that year. A minimum percentage of items dispensed subject to co-payment (4%) was used to ensure representation of treatments for a range of conditions, both chronic and acute, and included products also available without prescription, although at reduced dose, under supervised sale at community pharmacies: omeprazole (10 mg only), co-codamol (8 mg codeine/500 mg paracetamol only) and simvastatin (10 mg only).
GP practices in Wales were considered as being "treated" by the changes in co-payment policy (intervention), whereas practices in NE England were not (control). We employed a difference-in-difference (DiD) approach (Blundell & MaCurdy, 1999; Cameron and Trivedi, 2005) to measure this effect. During the course of phased abolition, a total of four interventions took place: a reduction from £6 to £5, £5 to £4, £4 to £3, and £3 to £0. The second intervention (from £5 to £4) took place in April 2005 which was only 6 months after the first intervention in October 2004. The remaining two interventions occurred yearly thereafter. We considered a 12-month pre-intervention and 12-month post-intervention period. For consistency, we excluded the 6-month time window of the second intervention period (October 2004 to March 2005) from the analysis. Number of items dispensed subject to co-payment/total number of items dispensed.
*The two strengths for amoxicillin were analysed separately but are considered a single medicine among the 14 medicines selected for this study.
**e/c = enteric coated. 
| Analysis
The econometric model is shown in Equation 1 using 24-month practice-level time series dispensing data. The outcome, Y it , measures the dispensing rate (number of items per 1,000 population) dispensed by practice i in month t and is modelled as a function of practice fixed effects (u i ) and time fixed effects (v t ) and random error term with zero mean (ε it ). We define a variable AREA it which takes a value 1 if the practice is in Wales and another variable INTV it which equals 1 if the observation belongs to the period after the policy intervention.
The time fixed effects are months over 2-year time-window that are represented by 23 dummy variables, with October 2003 being the reference category. The use of monthly dummies in model 1 accounts for time trends, and their coefficients show how the mean dispensing rates change over time, conditional on practice effects. The model is also adjusted for season, w s (3 quarterly dummies, with "October to December" being considered as the reference category and not included in the model). The coefficient of the interaction term, γ, indicates how dispensing rates differed between Wales and NE England in the last 12 months after the policy intervention, conditional on the practice and time effects.
The variance of a practice dispensing rate is inversely proportional to practice list size, and these varied substantially between practices, hence model 1 is weighted by list size. The effect is to give more weight to large practices whose rates are likely to show smaller random fluctuations than small practices.
As a DiD approach assumes that trends in intervention and control areas are similar before introducing the intervention, we carried out a pre-trends test over 3 separate pre-intervention time periods 
where t represents the month since the start of the data point, β is an estimate of the monthly trend in NE England, and ρ is the difference in monthly trend between Wales and NE England. The null hypothesis is that ρ = 0. The regression models were estimated using a weighted least-square method, with robust standard error corrected for heteroscedasticity. A crude price elasticity of prescription medicines utilisation in Wales was then calculated using the formula Price elasticity ¼ Percentage change in average medicines utilisation Percentage change in average perscription co−payment Since the study investigated interventions covering three time windows, our Analysis 1 covers a study period of 2 years when co-payment was £6 and £4, Analysis 2 covers a study period of 2 years when co-payment was £4 and £3, and, finally, Analysis 3 covers a study period of 2 years when co-payment was £3 and £0 in Wales.
The study received ethics approval from the South Wales Research Ethics Committee, reference 06/WSE02/31. Table 3 provides descriptive statistics of dispensing and co-payment data for three analyses covering study periods defined in Section 2.
| RESULTS
Results from pre-trends testing suggest that we were not able to reject the null hypothesis in all three analyses (ρ = 0.43, 95% CI [−3.4, 4.3] , ρ = 0.84, 95% CI [−3.5, 5.2], and ρ = 1.4, 95% CI [−3.3, 6 .1] in Analyses 1, 2, and 3, respectively). Table 3 shows that monthly dispensing of 14 selected medicines increased after the intervention in all three analyses and in both areas. However, the increase was greater in Wales than in NE England (33.1, 13.73, and 14.02 items; per practice per 1,000 population) versus 21.21, 7.05, and 4.36 items in Analyses 1, 2, and 3, respectively.
The DiD model suggests that, compared to NE England, Welsh dispensing increased in all analyses (p < .0001); however, the increase was smaller in Analysis 2 when co-payment was reduced to £3 from £4 (Table 4) .
The 11.93 items (per practice per 1,000 population) increase in Welsh dispensing of 14 selected medicines is equivalent to roughly 7.7% increase of the average Welsh dispensing during the period when prescription co-payment was £6 and £4 (Analysis 1, Table 5 ). Corresponding increases in Analyses 2 and 3 were 3.4% and 4.5%, respectively. Note. Analysis 1 covers 2 years of study period when co-payment in Wales was £6 and £4. Analysis 2 covers 2 years study period when co-payment in Wales was £4 and £3. Analysis 3 covers 2 years study period when co-payment in Wales was £3 and £0. Note. Analysis 1 covers 2 years of study period when co-payment in Wales was £6 and £4. Analysis 2 covers 2 years study period when co-payment in Wales was £4 and £3. Analysis 3 covers 2 years study period when co-payment in Wales was £3 and £0.
We estimated a crude price elasticity of medicines utilisation as −0.23, −0.13, and −0.04 from Analyses 1, 2, and 3, respectively.
| DISCUSSION
Our results suggest that the effect on dispensing of changing co-payment levels is not negligible. The Welsh policy was introduced with an explicit aim to improve health through removal of a (perceived) obstacle to those on low incomes obtaining the medicines they need (Welsh Assembly Government, 2003) . There is evidence that co-payment poses a barrier to adherence to treatment (Schafheutle, 2003) . The increase in dispensing rates for the 14 selected medicines therefore suggests that there may have been a group of nonexempt patients in Wales who were not fully adherent with prescribed treatment before the policy was introduced. The policy may therefore have contributed to reducing patients' non-adherence which in principle should produce an increase in health. A separate study undertaken by the authors suggested that the Welsh policy did not have an impact on consumption of medicines available without prescription from pharmacies (Groves et al., 2010) .
The price elasticity of utilisation estimates of −0.23, −0.13, and −0.04 for the three study periods, respectively, suggest that by the time the co-payment had fallen to a very low level (£3 per item), much of the effect had already occurred and a further fall to zero (abolition) had a lesser impact on dispensing rates than the earlier reductions.
Our study suggests that the utilisation of prescription medicines in Wales is inelastic and implies that consumers are not particularly responsive to changes in co-payments at these levels. This is not uncommon for a tax-financed health care system such as that in the UK, suggesting that consumers in publicly funded health systems appear to be less sensitive to changes in out-of-pocket expenses than consumers in other types of insurance systems (Gemmill et al., 2008) .
The low price elasticity estimates here may be due to several factors. First, those patients whose utilisation is likely to be most sensitive to changes in price, that is, those on very low incomes, were already exempt from co-payment. Second, elasticity is commonly estimated for small changes in price; here, the reductions happened in relatively large increments.
One advantage of our study was its ability to exploit a situation in which the policy on prescription co-payment changed in one area while remaining virtually constant in real terms in another with similar populations and local prescribing policies. Thus differences in dispensing could reasonably be assumed to be due to the Welsh policy on price. A disadvantage of our study, however, was the omission of the 6-month period when the prescription charged moved from £5 to £4, which may have coincided with the highest price elasticity of utilisation. There may also be unobserved confounding factors that were not controlled by comparison with the NE England.
| CONCLUSIONS
Abolition of co-payments has had a positive but small effect on dispensing rates in Wales. The magnitude of the impact of reductions in co-payment shown in this study appears to be broadly similar to those of increases in co-payment shown from previous studies. Use of a comparator area avoided the need to use questionable proxies to account for confounding variables, but this approach is only possible in rare situations.
Disaggregating the data into three time periods showed most of the effect occurred in response to the earlier reductions from relatively high levels. The response to abolishing a co-payment which has already fallen to a low level is less. Our study presents evidence that could support more detailed descriptions of underlying processes and qualitative analyses to help inform policy decisions.
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